Abstract
The aim of the present project work is to prepare PEGylated Anastrozole-BSA nanoparticles were prepared by desolvation technique. Prepared nanoparticles were characterized in terms of particle size, scanning electron microscope (SEM), fourier transform infraredspectroscopy (FTIR) and differential scanningcalorimetry (DSC). In-vitrorelease studies were performed in phosphate buffersaline pH 7.4 at 37˚±0.5˚C for 1month. The mean particle size of obtained nanoparticles was 150-400 nm and was apparently spherical in shape, with smooth surface. DSC is done for the stability test for pure drug and sample. The thermogram of drug has not shifted for in the formulation compare to pure drug thermogram hence, the stability of formulation is not changed . FT-IR studies demonstrated that the drug was not changed in the formulation during the fabrication process. The encapsulation efficiency was about 48%. The Anastrozole-BSA nanoparticles exhibit a most interesting release profile with small initial burst followed by slower and controlled release.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Clinical and Medical Case Reports and Reviews
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
